SEC filing registers 400,000 shares for Arcadia Biosciences stock

Published on 10/28/2026 at 06:24 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Second-quarter revenue was USD 1.443 million against USD 1.900 million expected. Arcadia Biosciences stock was last at USD 0.16 on October 27 versus a USD 0.1598 close.

Filing and operating figures

The September 30, 2026, filing registered 400,000 shares under an equity plan.
Second-quarter revenue reached USD 1.443 million against USD 1.900 million expected.
Arcadia Biosciences had a USD 365.7 thousand market capitalization and a USD 0.11 to USD 4.18 52-week range on October 27, 2026.

RKDA, US0390143032, Illustration mit AI erstellt.

Arcadia Biosciences (ISIN US0390143032) registered 400,000 shares under its 2026 Omnibus Equity Incentive Plan in a September 30, 2026, Form S-8 filing. The SEC filing places the employee-plan registration alongside the company financial disclosures. For investors, the filing matters because the share registration adds a concrete capital-structure item to a company with a small equity base.

400,000 shares enter the plan

The filing followed a USD 4.0 million private placement announced on June 12, 2026. The Arcadia Biosciences investor page lists that placement among its 2026 corporate updates.

The chronology shows three dated capital and operating steps: the USD 4.0 million placement on June 12, 2026, second-quarter results on August 13, 2026, and the 400,000-share S-8 registration on September 30, 2026. This sequence links financing, operating performance and employee compensation in less than four months.

What does the filing mean?

The operating backdrop remains demanding. According to Investing.com, second-quarter revenue was USD 1.443 million against USD 1.900 million expected, while net loss reached USD 6.266 million. The same page reports adjusted earnings per share of minus USD 2.09 against a forecast of minus USD 0.56. Those figures make the registered share count relevant: future dilution and cash discipline remain central to the investment case.

Small capitalization and wide range

Arcadia Biosciences operates in agricultural inputs and develops plant-derived health and wellness products, including crop-related innovations. The company profile identifies eight full-time employees, highlighting the compact scale behind the filing and the operating figures.

On October 27, 2026, the stock was last at USD 0.16 on the Nasdaq at 7:55 p.m. ET, after a USD 0.1598 close. The 52-week range was USD 0.11 to USD 4.18 and market capitalization was USD 365.7 thousand. The next market reading will therefore be judged against both the September filing and the company financial trajectory.